# OnCo record qin-shukui (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/qin-shukui/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "qin-shukui" ;
  schema:name "Shukui Qin"@en ;
  schema:alternateName "Qin Shu-Kui"@en, "秦叔逵"@en ;
  schema:description "Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use."@en ;
  schema:url <https://onco.cc/people/qin-shukui/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing> ;
  onco:tag "china" ;
  schema:jobTitle "Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)" ;
  onco:related <https://onco.cc/institutions/csco/> ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab-rivoceranib/>, <https://onco.cc/drugs/donafenib/>, <https://onco.cc/drugs/rivoceranib/> ;
  onco:trials <https://onco.cc/trials/cares-310/>, <https://onco.cc/trials/zgdh3/> .